Compounders Research Compare

Actuate Therapeutics Inc(ACTU)

Biotechnology · Fort Worth, TX

$0.87+0.06 (+6.83%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Fort Worth, TX

12 employees

actuatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Schmitt

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T13:25:15.694Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:15.694Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 20,932,728
Total debt · period ending 2026-06-30: 404,991
Cash · period ending 2026-06-30: 4,425,841
TTM operating income · period ending 2026-06-30: -20,772,595

FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACTU EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ACTU Competitors' EV/EBIT Ratio

Actuate Therapeutics Inc

Current

Market Cap

$20.93M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$21.90M

EV/EBIT Ratio

N/A

TTM Avg

21.00x

3Y Avg

21.00x

5Y Avg

21.00x

Cosmos Health Inc.

Market Cap

$18.82M

EV/EBIT Ratio

N/A

TTM Avg

64.12x

3Y Avg

126.81x

5Y Avg

126.81x

Estrella Immunopharma, Inc.

Market Cap

$18.77M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Atossa Therapeutics, Inc.

Market Cap

$24.44M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kyntra Bio, Inc.

Market Cap

$24.65M

EV/EBIT Ratio

N/A

TTM Avg

104.01x

3Y Avg

104.01x

5Y Avg

104.01x

Bionano Genomics, Inc.

Market Cap

$16.58M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dyadic International, Inc.

Market Cap

$16.54M

EV/EBIT Ratio

N/A

TTM Avg

188.96x

3Y Avg

135.60x

5Y Avg

135.60x

ABVC BioPharma, Inc.

Market Cap

$25.48M

EV/EBIT Ratio

N/A

TTM Avg

11456.84x

3Y Avg

11456.84x

5Y Avg

11456.84x

BioCardia, Inc.

Market Cap

$16.22M

EV/EBIT Ratio

N/A

TTM Avg

33.55x

3Y Avg

33.49x

5Y Avg

33.49x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Actuate Therapeutics Inc (ACTU)	$20.93M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$21.90M	N/A	21.00x	21.00x	21.00x
Cosmos Health Inc. (COSM)vs ›	$18.82M	N/A	64.12x	126.81x	126.81x
Estrella Immunopharma, Inc. (ESLA)vs ›	$18.77M	N/A	N/A	N/A	N/A
Atossa Therapeutics, Inc. (ATOS)vs ›	$24.44M	N/A	N/A	N/A	N/A
Kyntra Bio, Inc. (KYNB)vs ›	$24.65M	N/A	104.01x	104.01x	104.01x
Bionano Genomics, Inc. (BNGO)vs ›	$16.58M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.54M	N/A	188.96x	135.60x	135.60x
ABVC BioPharma, Inc. (ABVC)vs ›	$25.48M	N/A	11456.84x	11456.84x	11456.84x
BioCardia, Inc. (BCDA)vs ›	$16.22M	N/A	33.55x	33.49x	33.49x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics